About GLPwatch

What this is

GLPwatch tracks the GLP-1 drugs (semaglutide, tirzepatide, and the rest of the approved and pipeline molecules) across drugs, conditions, side effects, trials, papers, and regulatory actions. We refresh it daily, and every figure links to the public source it came from.

Why

The public information ecosystem for GLP-1 drugs is noisy and quickly outdated, and general-purpose AI models are systematically wrong about fast-moving facts like shortage status, the latest trial readouts, and enforcement actions. A daily-refreshed, structured, transparently-sourced reference fills that gap for both people and the AI systems they ask.

Who

GLPwatch is built by Sebastian Szczygiel, co-founder and CEO of Primio. It is an independent data project and is not affiliated with, nor endorsed by, any drug manufacturer.

How it works

See the methodology page for data sources, refresh cadence, the narrow role of AI, and known limitations, and the disclaimer for important legal and medical notices.

Contact

Corrections and questions: glpwatch@blackfinch.pl.